A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein; E. F. Smit; D. Planchard; D. W. Kim; J. Cadranel; T. De Pas; F. Dunphy; K. Udud; M. J. Ahn; N. H. Hanna; J. H. Kim; J. Mazieres; S. W. Kim; P. Baas; E. Rappold; S. Redhu; A. Puski; F. S. Wu; P. A. Jänne

doi:10.1093/annonc/mdv072

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, E. F. Smit, D. Planchard, D. W. Kim, J. Cadranel, T. De Pas, F. Dunphy, K. Udud, M. J. Ahn, N. H. Hanna, J. H. Kim, J. Mazieres, S. W. Kim, P. Baas, E. Rappold, S. Redhu, A. Puski, F. S. Wu, P. A. Jänne

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

270 Citations (Scopus)

Résumé

Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m² i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

langue originale	Anglais
Pages (de - à)	894-901
Nombre de pages	8
journal	Annals of Oncology
Volume	26
Numéro de publication	5
Les DOIs	https://doi.org/10.1093/annonc/mdv072
état	Publié - 1 mai 2015

Accès au document

10.1093/annonc/mdv072

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D. W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M. J., Hanna, N. H., Kim, J. H., Mazieres, J., Kim, S. W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., & Jänne, P. A. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 26(5), 894-901. https://doi.org/10.1093/annonc/mdv072

@article{9d1bf4c7478944fc9a10a3132915f5f2,

title = "A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)",

abstract = "Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.",

keywords = "Docetaxel, KRAS, MEK inhibitor, NSCLC, Progression-free survival, Trametinib",

author = "Blumenschein, {George R.} and Smit, {E. F.} and D. Planchard and Kim, {D. W.} and J. Cadranel and {De Pas}, T. and F. Dunphy and K. Udud and Ahn, {M. J.} and Hanna, {N. H.} and Kim, {J. H.} and J. Mazieres and Kim, {S. W.} and P. Baas and E. Rappold and S. Redhu and A. Puski and Wu, {F. S.} and J{\"a}nne, {P. A.}",

year = "2015",

month = may,

day = "1",

doi = "10.1093/annonc/mdv072",

language = "English",

volume = "26",

pages = "894--901",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "5",

}

Blumenschein, GR, Smit, EF, Planchard, D, Kim, DW, Cadranel, J, De Pas, T, Dunphy, F, Udud, K, Ahn, MJ, Hanna, NH, Kim, JH, Mazieres, J, Kim, SW, Baas, P, Rappold, E, Redhu, S, Puski, A, Wu, FS & Jänne, PA 2015, 'A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)', Annals of Oncology, VOL. 26, Numéro 5, p. 894-901. https://doi.org/10.1093/annonc/mdv072

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). / Blumenschein, George R.; Smit, E. F.; Planchard, D. et al.
Dans: Annals of Oncology, Vol 26, Numéro 5, 01.05.2015, p. 894-901.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

AU - Blumenschein, George R.

AU - Smit, E. F.

AU - Planchard, D.

AU - Kim, D. W.

AU - Cadranel, J.

AU - De Pas, T.

AU - Dunphy, F.

AU - Udud, K.

AU - Ahn, M. J.

AU - Hanna, N. H.

AU - Kim, J. H.

AU - Mazieres, J.

AU - Kim, S. W.

AU - Baas, P.

AU - Rappold, E.

AU - Redhu, S.

AU - Puski, A.

AU - Wu, F. S.

AU - Jänne, P. A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

AB - Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

KW - Docetaxel

KW - KRAS

KW - MEK inhibitor

KW - NSCLC

KW - Progression-free survival

KW - Trametinib

UR - http://www.scopus.com/inward/record.url?scp=84929071676&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv072

DO - 10.1093/annonc/mdv072

M3 - Article

C2 - 25722381

AN - SCOPUS:84929071676

SN - 0923-7534

VL - 26

SP - 894

EP - 901

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

ER -